---
document_datetime: 2025-12-29 12:25:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/amifampridine-serb.html
document_name: amifampridine-serb.html
version: success
processing_time: 0.1032984
conversion_datetime: 2025-12-30 01:19:17.895837
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Amifampridine SERB

[RSS](/en/individual-human-medicine.xml/67567)

##### Authorised

This medicine is authorised for use in the European Union

amifampridine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Amifampridine SERB](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Amifampridine Serb is a medicine used to treat the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a disease in which patients have muscle weakness because of a failure of the nerves to transmit electrical impulses to the muscles.

Amifampridine Serb contains the active substance amifampridine and is a 'generic medicine'. This means that Amifampridine Serb contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Firdapse. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Amifampridine Serb used?

Amifampridine Serb can only be obtained with a prescription and treatment with this medicine should only be started under the supervision of a doctor experienced in treating LEMS.

The recommended starting dose of Amifampridine Serb is 15 mg per day, which can be increased by 5 mg every four to five days up to a maximum of 60 mg per day. Amifampridine Serb is taken in divided doses, three or four times a day, and a single dose should not be more than 20 mg. Amifampridine Serb should be taken with food.

For more information about using Amifampridine Serb, see the package leaflet or contact your doctor or pharmacist.

## How does Amifampridine Serb work?

For muscles to contract, nerves have to transmit electrical impulses to the muscles through a chemical messenger called acetylcholine. Acetylcholine is released from the nerve endings during a period of 'depolarisation'. The active substance in Amifampridine Serb, amifampridine, is a potassium channel blocker, which prevents charged potassium particles from leaving the nerve cells. This prolongs the period of depolarisation, allowing more time for the nerves to release acetylcholine and so stimulate the muscles to contract.

## How has Amifampridine Serb been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Firdapse, and do not need to be repeated for Amifampridine Serb.

As for every medicine, the company provided data on the quality of Amifampridine Serb. There was no need for 'bioequivalence' studies to investigate whether Amifampridine Serb is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Amifampridine Serb is the same as the reference medicine and the active substance in both products is expected to be absorbed in the same way.

## What are the benefits and risks of Amifampridine Serb?

Because Amifampridine Serb is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Amifampridine Serb authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Amifampridine Serb has been shown to be comparable to Firdapse. Therefore, the Agency's view was that, as for Firdapse, the benefits of Amifampridine Serb outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Amifampridine Serb?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Amifampridine Serb have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Amifampridine Serb are continuously monitored. Suspected side effects reported with Amifampridine Serb are carefully evaluated and any necessary action taken to protect patients.

## Other information about Amifampridine Serb

Amifampridine Serb received a marketing authorisation valid throughout the EU on 19 May 2022.

Amifampridine SERB : EPAR - Medicine Overview

Reference Number: EMA/196211/2022

English (EN) (156.74 KB - PDF)

**First published:** 24/05/2022

[View](/en/documents/overview/amifampridine-serb-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-144)

български (BG) (182.19 KB - PDF)

**First published:**

24/05/2022

[View](/bg/documents/overview/amifampridine-serb-epar-medicine-overview_bg.pdf)

español (ES) (158.54 KB - PDF)

**First published:**

24/05/2022

[View](/es/documents/overview/amifampridine-serb-epar-medicine-overview_es.pdf)

čeština (CS) (179.43 KB - PDF)

**First published:**

24/05/2022

[View](/cs/documents/overview/amifampridine-serb-epar-medicine-overview_cs.pdf)

dansk (DA) (156.67 KB - PDF)

**First published:**

24/05/2022

[View](/da/documents/overview/amifampridine-serb-epar-medicine-overview_da.pdf)

Deutsch (DE) (160.21 KB - PDF)

**First published:**

24/05/2022

[View](/de/documents/overview/amifampridine-serb-epar-medicine-overview_de.pdf)

eesti keel (ET) (145.37 KB - PDF)

**First published:**

24/05/2022

[View](/et/documents/overview/amifampridine-serb-epar-medicine-overview_et.pdf)

ελληνικά (EL) (183.16 KB - PDF)

**First published:**

24/05/2022

[View](/el/documents/overview/amifampridine-serb-epar-medicine-overview_el.pdf)

français (FR) (158.09 KB - PDF)

**First published:**

24/05/2022

[View](/fr/documents/overview/amifampridine-serb-epar-medicine-overview_fr.pdf)

hrvatski (HR) (176.7 KB - PDF)

**First published:**

24/05/2022

[View](/hr/documents/overview/amifampridine-serb-epar-medicine-overview_hr.pdf)

italiano (IT) (155.97 KB - PDF)

**First published:**

24/05/2022

[View](/it/documents/overview/amifampridine-serb-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (194.5 KB - PDF)

**First published:**

24/05/2022

[View](/lv/documents/overview/amifampridine-serb-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (178.77 KB - PDF)

**First published:**

24/05/2022

[View](/lt/documents/overview/amifampridine-serb-epar-medicine-overview_lt.pdf)

magyar (HU) (178.75 KB - PDF)

**First published:**

24/05/2022

[View](/hu/documents/overview/amifampridine-serb-epar-medicine-overview_hu.pdf)

Malti (MT) (181.2 KB - PDF)

**First published:**

24/05/2022

[View](/mt/documents/overview/amifampridine-serb-epar-medicine-overview_mt.pdf)

Nederlands (NL) (158.37 KB - PDF)

**First published:**

24/05/2022

[View](/nl/documents/overview/amifampridine-serb-epar-medicine-overview_nl.pdf)

polski (PL) (183.15 KB - PDF)

**First published:**

24/05/2022

[View](/pl/documents/overview/amifampridine-serb-epar-medicine-overview_pl.pdf)

português (PT) (158.18 KB - PDF)

**First published:**

24/05/2022

[View](/pt/documents/overview/amifampridine-serb-epar-medicine-overview_pt.pdf)

română (RO) (175.26 KB - PDF)

**First published:**

24/05/2022

[View](/ro/documents/overview/amifampridine-serb-epar-medicine-overview_ro.pdf)

slovenčina (SK) (179.27 KB - PDF)

**First published:**

24/05/2022

[View](/sk/documents/overview/amifampridine-serb-epar-medicine-overview_sk.pdf)

slovenščina (SL) (175.89 KB - PDF)

**First published:**

24/05/2022

[View](/sl/documents/overview/amifampridine-serb-epar-medicine-overview_sl.pdf)

Suomi (FI) (155.99 KB - PDF)

**First published:**

24/05/2022

[View](/fi/documents/overview/amifampridine-serb-epar-medicine-overview_fi.pdf)

svenska (SV) (155.74 KB - PDF)

**First published:**

24/05/2022

[View](/sv/documents/overview/amifampridine-serb-epar-medicine-overview_sv.pdf)

Amifampridine Serb : EPAR - Risk management plan summary

English (EN) (78.16 KB - PDF)

**First published:** 24/05/2022

[View](/en/documents/rmp-summary/amifampridine-serb-epar-risk-management-plan-summary_en.pdf)

## Product information

Amifampridine Serb : EPAR - Product Information

English (EN) (233.15 KB - PDF)

**First published:** 24/05/2022

[View](/en/documents/product-information/amifampridine-serb-epar-product-information_en.pdf)

[Other languages (25)](#file-language-dropdown-551)

български (BG) (323.07 KB - PDF)

**First published:**

24/05/2022

[View](/bg/documents/product-information/amifampridine-serb-epar-product-information_bg.pdf)

español (ES) (251.02 KB - PDF)

**First published:**

24/05/2022

[View](/es/documents/product-information/amifampridine-serb-epar-product-information_es.pdf)

čeština (CS) (297.13 KB - PDF)

**First published:**

24/05/2022

[View](/cs/documents/product-information/amifampridine-serb-epar-product-information_cs.pdf)

dansk (DA) (237.14 KB - PDF)

**First published:**

24/05/2022

[View](/da/documents/product-information/amifampridine-serb-epar-product-information_da.pdf)

Deutsch (DE) (253.52 KB - PDF)

**First published:**

24/05/2022

[View](/de/documents/product-information/amifampridine-serb-epar-product-information_de.pdf)

eesti keel (ET) (208.38 KB - PDF)

**First published:**

24/05/2022

[View](/et/documents/product-information/amifampridine-serb-epar-product-information_et.pdf)

ελληνικά (EL) (341.58 KB - PDF)

**First published:**

24/05/2022

[View](/el/documents/product-information/amifampridine-serb-epar-product-information_el.pdf)

français (FR) (428.59 KB - PDF)

**First published:**

24/05/2022

[View](/fr/documents/product-information/amifampridine-serb-epar-product-information_fr.pdf)

hrvatski (HR) (278.39 KB - PDF)

**First published:**

24/05/2022

[View](/hr/documents/product-information/amifampridine-serb-epar-product-information_hr.pdf)

íslenska (IS) (219.98 KB - PDF)

**First published:**

24/05/2022

[View](/is/documents/product-information/amifampridine-serb-epar-product-information_is.pdf)

Gaeilge (GA) (255.13 KB - PDF)

**First published:**

24/05/2022

[View](/ga/documents/product-information/amifampridine-serb-epar-product-information_ga.pdf)

italiano (IT) (205.66 KB - PDF)

**First published:**

24/05/2022

[View](/it/documents/product-information/amifampridine-serb-epar-product-information_it.pdf)

latviešu valoda (LV) (296.04 KB - PDF)

**First published:**

24/05/2022

[View](/lv/documents/product-information/amifampridine-serb-epar-product-information_lv.pdf)

lietuvių kalba (LT) (279.47 KB - PDF)

**First published:**

24/05/2022

[View](/lt/documents/product-information/amifampridine-serb-epar-product-information_lt.pdf)

magyar (HU) (283.36 KB - PDF)

**First published:**

24/05/2022

[View](/hu/documents/product-information/amifampridine-serb-epar-product-information_hu.pdf)

Malti (MT) (412.64 KB - PDF)

**First published:**

24/05/2022

[View](/mt/documents/product-information/amifampridine-serb-epar-product-information_mt.pdf)

Nederlands (NL) (305.75 KB - PDF)

**First published:**

24/05/2022

[View](/nl/documents/product-information/amifampridine-serb-epar-product-information_nl.pdf)

norsk (NO) (220.01 KB - PDF)

**First published:**

24/05/2022

[View](/no/documents/product-information/amifampridine-serb-epar-product-information_no.pdf)

polski (PL) (340.24 KB - PDF)

**First published:**

24/05/2022

[View](/pl/documents/product-information/amifampridine-serb-epar-product-information_pl.pdf)

português (PT) (204.17 KB - PDF)

**First published:**

24/05/2022

[View](/pt/documents/product-information/amifampridine-serb-epar-product-information_pt.pdf)

română (RO) (299.23 KB - PDF)

**First published:**

24/05/2022

[View](/ro/documents/product-information/amifampridine-serb-epar-product-information_ro.pdf)

slovenčina (SK) (290.31 KB - PDF)

**First published:**

24/05/2022

[View](/sk/documents/product-information/amifampridine-serb-epar-product-information_sk.pdf)

slovenščina (SL) (271.19 KB - PDF)

**First published:**

24/05/2022

[View](/sl/documents/product-information/amifampridine-serb-epar-product-information_sl.pdf)

Suomi (FI) (262.15 KB - PDF)

**First published:**

24/05/2022

[View](/fi/documents/product-information/amifampridine-serb-epar-product-information_fi.pdf)

svenska (SV) (248.23 KB - PDF)

**First published:**

24/05/2022

[View](/sv/documents/product-information/amifampridine-serb-epar-product-information_sv.pdf)

19/05/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Amifampridine Serb : EPAR - All authorised presentations

English (EN) (48.26 KB - PDF)

**First published:** 24/05/2022

[View](/en/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_en.pdf)

[Other languages (25)](#file-language-dropdown-310)

български (BG) (65.99 KB - PDF)

**First published:**

24/05/2022

[View](/bg/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.94 KB - PDF)

**First published:**

24/05/2022

[View](/es/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.58 KB - PDF)

**First published:**

24/05/2022

[View](/cs/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.09 KB - PDF)

**First published:**

24/05/2022

[View](/da/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.67 KB - PDF)

**First published:**

24/05/2022

[View](/de/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (104.63 KB - PDF)

**First published:**

24/05/2022

[View](/et/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (65.81 KB - PDF)

**First published:**

24/05/2022

[View](/el/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_el.pdf)

français (FR) (48.85 KB - PDF)

**First published:**

24/05/2022

[View](/fr/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.79 KB - PDF)

**First published:**

24/05/2022

[View](/hr/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.34 KB - PDF)

**First published:**

24/05/2022

[View](/is/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_is.pdf)

Gaeilge (GA) (48.66 KB - PDF)

**First published:**

24/05/2022

[View](/ga/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_ga.pdf)

italiano (IT) (49.19 KB - PDF)

**First published:**

24/05/2022

[View](/it/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.83 KB - PDF)

**First published:**

24/05/2022

[View](/lv/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.28 KB - PDF)

**First published:**

24/05/2022

[View](/lt/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.25 KB - PDF)

**First published:**

24/05/2022

[View](/hu/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.39 KB - PDF)

**First published:**

24/05/2022

[View](/mt/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.25 KB - PDF)

**First published:**

24/05/2022

[View](/nl/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.05 KB - PDF)

**First published:**

24/05/2022

[View](/no/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_no.pdf)

polski (PL) (56 KB - PDF)

**First published:**

24/05/2022

[View](/pl/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.43 KB - PDF)

**First published:**

24/05/2022

[View](/pt/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.57 KB - PDF)

**First published:**

24/05/2022

[View](/ro/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (58.9 KB - PDF)

**First published:**

24/05/2022

[View](/sk/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.27 KB - PDF)

**First published:**

24/05/2022

[View](/sl/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.39 KB - PDF)

**First published:**

24/05/2022

[View](/fi/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.89 KB - PDF)

**First published:**

24/05/2022

[View](/sv/documents/all-authorised-presentations/amifampridine-serb-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Amifampridine SERB Active substance amifampridine phosphate International non-proprietary name (INN) or common name amifampridine Therapeutic area (MeSH)

- Lambert-Eaton Myasthenic Syndrome
- Paraneoplastic Syndromes, Nervous System
- Nervous System Neoplasms
- Paraneoplastic Syndromes
- Nervous System Diseases
- Autoimmune Diseases of the Nervous System
- Neurodegenerative Diseases
- Neuromuscular Diseases
- Neuromuscular Junction Diseases
- Immune System Diseases
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Cancer
- Neoplasms

Anatomical therapeutic chemical (ATC) code N07XX05

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

## Authorisation details

EMA product number EMEA/H/C/005839

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

SERB SA

Avenue Louise 480

Opinion adopted 24/03/2022 Marketing authorisation issued 19/05/2022

## Assessment history

## Initial marketing authorisation documents

Amifampridine Serb : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/216122/2022

English (EN) (276.77 KB - PDF)

**First published:** 24/05/2022

[View](/en/documents/assessment-report/amifampridine-serb-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Amifampridine SERB

Adopted

Reference Number: EMA/CHMP/122713/2022

English (EN) (149.73 KB - PDF)

**First published:** 25/03/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-amifampridine-serb_en.pdf)

#### News on Amifampridine SERB

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022) 25/03/2022

**This page was last updated on** 24/05/2022

## Share this page

[Back to top](#main-content)